Immunicom
In the 25 years since founding DJM Capital Partners, D. John Miller’s sharp entrepreneurial instincts, impeccable market timing and real estate investment acumen have grown the company to $1 Billion in assets.
In commercial real estate for over 30 years, Miller formed his company in the early 90s to participate in the massive liquidation of commercial real estate resulting from the savings and loan crisis, opportunistically acquiring $75 million in bank-owned assets in California, selling the portfolio at a significant return.
With a smart acquisitions strategy and value-add approach through property renovation, re-leasing, change of use, and creative financing, the company’s growing portfolio, held by DJM’s various equity funds, continues to generate attractive returns for investors.
Miller holds a B.A. in Political Science from the University of California at Berkeley, where he graduated cum laude.
This person is not in the org chart
This person is not in any offices
Immunicom
Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients’ quality of life – all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicom's cancer therapy can allow the body’s natural immune system to directly attack cancer while enhancing the effects of other cancer treatments that may be used concurrently.